Earlier initiation is reshaping patient journeys: Patients are starting GLP1 therapy within weeks of diagnosis, underscoring the need for streamlined access pathways and payer alignment to reduce delays, especially in Medicare populations
Without adequate blood supply, tissue cannot heal
Products higher in protein, fiber, and micronutrients align with smaller portion sizes and reduced appetite
Comparison of severity and frequency of side effects between semaglutide and Ozempic Since compounded semaglutide is not FDA-approved, the frequency and severity of side effects may vary depending on the formulation and individual response
Making b12 deficiency feel cured
Why Medicaid Restrictions Push Patients Toward Direct-Pay Options When Medicaid denies or delays GLP-1 coverage for weight loss, patients face a critical choice: wait months for administrative appeals or pursue direct-pay compounded medications from licensed pharmacies